Drugs / Neugranin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01126190 | Jun 2010 → Feb 2012 | neutropenia | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Neugranin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01126190 ↗ |
| Modality | Protein / enzyme biologic | “Neugranin (Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor)” NCT01126190 ↗ |
| Route | Subcutaneous | “Neugranin 40 mg, administered by SC injection once per chemotherapy cycle” NCT01126190 ↗ |